Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Adamis Pharmaceuticals Corporation Announces Resignation of Roshawn A. Blunt as Director, Effective October 1, 2021

09/13/2021 | 04:35pm EDT

On September 7, 2021, Roshawn A. Blunt, a director of the Adamis Pharmaceuticals Corporation and a member of the Audit Committee, Compensation Committee and Nominating and Governance Committee, notified the Company that for personal reasons, effective as of October 1, 2021, she was resigning as a director of the Company.


© S&P Capital IQ 2021
All news about ADAMIS PHARMACEUTICALS CORPORATION
10/18ADAMIS PHARMACEUTICALS : New High-Dose Naloxone Product for the Treatment of Opioid Overdo..
PU
10/18ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
10/18Health Care Stocks Sputtering in Late Trade
MT
10/18Health Care Stocks Weighing on Broader Monday Markets
MT
10/18Adamis Pharma Shares Rise 16% After FDA Approves Zimhi for Opioid Overdose
DJ
10/18ADAMIS PHARMACEUTICALS : Gets FDA Approval For Opioid Overdose Injection; Shares Surge
MT
10/18Wall Street Set for Positive Open as Earnings-Heavy Week Kicks Off; China GDP Growth Sl..
MT
10/18Top Premarket Gainers
MT
10/18ADAMIS PHARMACEUTICALS : Receives FDA Approval for ZIMHI
AQ
10/18Adamis Pharmaceuticals Corporation Receives FDA Approval for ZIMHI
CI
More news
Financials (USD)
Sales 2021 22,0 M - -
Net income 2021 -24,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,41x
Yield 2021 -
Capitalization 162 M 162 M -
Capi. / Sales 2021 7,38x
Capi. / Sales 2022 16,2x
Nbr of Employees 130
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 1,09 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Dennis J. Carlo President, Chief Executive Officer & Director
David C. Benedicto Chief Financial & Accounting Officer
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Karen K. Daniels Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ADAMIS PHARMACEUTICALS CORPORATION124.70%162
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979